Targeting specific KRAS mutations in cancer treatment
Official title: Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
Funded at Enfuego Therapeutics INC. · NIH-11116069 · Data updated 2026-11-12
This study is exploring new treatments for people with aggressive cancers like lung, colon, and pancreatic cancer that have a specific mutation called KRAS G12V, using a special technique to target and turn off the bad gene while keeping healthy cells safe.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enfuego Therapeutics INC. NIH-funded |
| Lab location | 1 site (Pittsboro, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $919,020 |
| NIH project number | 4R44CA284932-02 |
| Project ID | NIH-11116069 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, colon cancer, or pancreatic cancer that harbor the KRAS G12V mutation.
✕Less likely to help
Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on developing new therapies that specifically target the KRAS G12V mutation, which is prevalent in several aggressive cancers such as lung, colon, and pancreatic cancers. By utilizing RNA interference (RNAi) technology, the approach aims to selectively silence the mutant KRAS gene while preserving the normal gene function in healthy tissues. This targeted method could potentially overcome the challenges faced in treating cancers driven by KRAS mutations, which have been historically difficult to address with conventional therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with KRAS G12V mutant cancers.
How similar studies have gone: While there have been some advancements in targeting KRAS mutations, this specific approach using RNAi for the G12V mutation is relatively novel and has not been extensively tested.
Where this research is happening
-
Enfuego Therapeutics INC.
Pittsboro, United States Active
Researchers
- Principal investigator: Stanland, Lyla — Enfuego Therapeutics INC.
- Study coordinator: Stanland, Lyla
Related research
Other NIH-funded projects on the same topics.
-
Overcoming KRAS Drug Resistance with Targeted KRAS-G12V and TEAD Chimeras
This grant aims to develop a targeted approach to treat KRAS-driven cancers by combining mutant KRAS targeting with TEAD pathway engagement to overcome resistance.
-
Therapy targeting KRAS G12V mutations in lung, colon, and pancreatic cancers
Developing a precision RNA-based therapy that aims to shut off the KRAS G12V mutation in people whose tumors are driven by that change.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.